J. Quiroga

M. Diago, V. Carreño, J. Quiroga, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Patterns of immune responses to the host-encoded GOR and hepatitis C virus core-derived epitopes with relation to hepatitis C viremia, genotypes, and liver disease severity.

V. Carreño, S. Navas, J. Quiroga, 1996, The Journal of infectious diseases.

Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome

Changcai Wang, V. Carreño, J. van Binsbergen, 1995, Hepatology.

Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group

A. Moreno, V. Carreño, I. Castillo, 1990 .

Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses.

A. Moreno, V. Carreño, J. Quiroga, 1989, Journal of hepatology.

Impact of Isolated Hepatitis C Virus (HCV) Core-Specific Antibody Detection and Viral RNA Amplification among HCV-Seronegative Dialysis Patients at Risk for Infection

J. Bartolomé, V. Carreño, M. Arenas, 2014, Journal of Clinical Microbiology.

Serum levels of anti‐NS4a and anti‐NS5a predict treatment response of patients with chronic hepatitis C

H. Van Vlierberghe, O. Weiland, G. Leroux-Roels, 2007, Journal of medical virology.

Association of HLA-DR genes with mild idiopathic adulthood biliary ductopenia

V. Carreño, J. Quiroga, M. Pardo, 2001, American Journal of Gastroenterology.

Presence of HCV‐RNA after ultracentrifugation of serum samples during the follow‐up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection

V. Carreño, G. Barril, I. Castillo, 2009, Alimentary pharmacology & therapeutics.

Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein.

O. Weiland, M. Chen, G. Leroux-Roels, 2001, The Journal of general virology.

Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses.

O. Weiland, G. Leroux-Roels, M. Sällberg, 2004, Journal of hepatology.

Assessment of hepatitis B virus DNA levels in chronic HBsAg carriers with or without hepatitis delta virus superinfection.

V. Carreño, J. Quiroga, C. Bas, 1988, Journal of hepatology.

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.

V. Carreño, M. Rico, S. Navas, 1999, Antiviral research.

Sequence of non-structural regions 3 and 5 of hepatitis C virus genomes from Spanish patients: existence of a predominant variant related to type 1b.

J. Bartolomé, V. Carreño, I. Castillo, 1995, The Journal of general virology.

Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells.

V. Carreño, S. Navas, I. Castillo, 1993, Journal of hepatology.

Concordance of hepatitis C virus typing methods based on restriction fragment length polymorphism analysis in 5' noncoding region and NS4 serotyping, but not in core PCR or a line probe assay

V. Carreño, S. Navas, I. Castillo, 1997, Journal of clinical microbiology.

Evidence of subtype-specific antibodies to antigenic epitopes in the NS5 region of hepatitis C virus in the circulation of patients with chronic hepatitis C.

J. Bartolomé, V. Carreño, I. Castillo, 1994, Clinical and diagnostic laboratory immunology.

An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C.

V. Carreño, J. Quiroga, L. Tapia, 1993, Journal of hepatology.

Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon‐alpha

V. Carreño, I. Castillo, J. Quiroga, 1992, Journal of medical virology.

Biological properties of interleukin‐12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection

V. Carreño, J. Quiroga, 1997, Journal of viral hepatitis.

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.

V. Carreño, S. Navas, J. Quiroga, 1998, Cytokine.

Role of haemodialysis and hepatitis c virus infection in spontaneous and induced cytokine production of patients with chronic renal disease.

V. Carreño, C. Caramelo, M. Rico, 2000, Cytokine.

Identification of different degrees of hepatitis B virus (HBV) replication by serological (HBV-DNAp, HBcAg and HBV-DNA) and histological (HBcAg) methods.

V. Carreño, J. Quiroga, J. Bartolomé, 2008, Liver.

Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection.

J. Bartolomé, V. Carreño, J. Quiroga, 1987, Journal of hepatology.

Interleukin‐28B polymorphisms and interferon gamma inducible protein‐10 serum levels in seronegative occult hepatitis C virus infection

J. Bartolomé, V. Carreño, I. Castillo, 2016, Journal of medical virology.

Hepatitis C virus infection in the family setting of patients with occult hepatitis C

J. Bartolomé, V. Carreño, G. Barril, 2009, Journal of medical virology.

Hepatitis C virus replication in patients with occult hepatitis C virus infection

J. Bartolomé, V. Carreño, I. Castillo, 2009, Hepatology.

Detection of serum inhibitory factor for lymphocyte stimulation in chronic viral hepatitis: relationship with the replication level.

V. Carreño, I. Castillo, J. Quiroga, 2008, Liver.

Risks and Benefits of Interferon-α in the Treatment of Hepatitis

V. Carreño, E. Marriott, J. Quiroga, 1995 .

Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children.

M. Manns, V. Carreño, M. J. Ruá, 1991, Journal of hepatology.

A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules.

S. Ramón y. Cajal, V. Carreño, J. Quiroga, 1987, Antiviral research.

Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-alpha.

V. Carreño, M. Rico, J. Quiroga, 2001, Antiviral research.

Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins.

V. Carreño, J. Quiroga, Mario Fernández, 2003, The Journal of general virology.

Pilot study of recombinant human granulocyte‐macrophage colony–stimulating factor in the treatment of chronic hepatitis B

J. Bartolomé, V. Carreño, G. Moraleda, 1993, Hepatology.

Changes in anti-idiotype antibodies against anti-HBs during recombinant interferon treatment of chronic hepatitis B.

V. Carreño, J. Quiroga, J. Porres, 1990, Journal of interferon research.

Elevation of 2',5'-oligoadenylate synthetase activity and HLA-I associated beta 2-microglobulin in response to recombinant interferon-gamma administration in chronic HBeAg-positive hepatitis.

V. Carreño, J. Quiroga, J. Porres, 1988, Journal of interferon research.

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody–positive patients

V. Carreño, F. Manzarbeitia, J. Quiroga, 2000, Hepatology.

Radioimmunoassay for DetectingHepatitisB Core Antigenin Serum from Patientswith ChronicHepatitisB Infection

J. Quiroga, Ignaclo Mora, Juan C. Porrea, 1985 .

Impaired interferon induction of human MxA protein in chronic hepatitis B virus infection

V. Carreño, J. Quiroga, M. Pardo, 1997, Journal of medical virology.

Detection of HBeAg/anti-HBe immune complexes in the reactivation of hepatitis B virus replication among anti-HBe chronic carriers.

V. Carreño, I. Castillo, J. Quiroga, 2008, Liver.

Changes in cytokine production during therapy with Granulocyte‐macrophage colony‐stimulating factor in patients with chronic hepatitis B

J. Quiroga, Julio Martín, Vicente Carreño, 1994, Hepatology.

IgM antibody to hepatitis C virus in acute and chronic hepatitis C

J. Bartolomé, V. Carreño, J. Quiroga, 1991, Hepatology.

Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C.

M. Diago, V. Carreño, J. Such, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.

D. Subirá, S. Castañón, V. Carreño, 2001, Hepatology.

High prevalence of occult hepatitis C virus infection in patients with chronic hepatitis B virus infection.

J. Bartolomé, V. Carreño, I. Castillo, 2013, Journal of medical microbiology.

New perspectives in occult hepatitis C virus infection.

J. Bartolomé, V. Carreño, I. Castillo, 2012, World journal of gastroenterology.

Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: a pilot study.

J. Bartolomé, V. Carreño, J. Ordi, 1988, Hepato-gastroenterology.

IgG and IgM autoantiidiotype antibodies against antibody to HBsAg in chronic hepatitis B

J. Bartolomé, J. Quiroga, J. Porres, 1988, Hepatology.

Genetic Diversity and Tissue Compartmentalization of the Hepatitis C Virus Genome in Blood Mononuclear Cells, Liver, and Serum from Chronic Hepatitis C Patients

V. Carreño, S. Navas, I. Castillo, 1998, Journal of Virology.

Liver membrane antibodies in chronic delta hepatitis.

V. Carreño, J. Quiroga, C. Bas, 1987, Digestion.

Protein composition of the hepatitis B virus e antigen in the natural course of disease and following interferon therapy

V. Carreño, G. Moraleda, I. Castillo, 1992, Journal of clinical microbiology.

Pegylated interferon‐α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers

R. Selgas, V. Carreño, G. Barril, 2004, Alimentary pharmacology & therapeutics.

Hepatitis E virus seroprevalence in acute viral hepatitis in a developed country confirmed by a supplemental assay

V. Carreño, I. Castillo, J. Quiroga, 1996, Journal of medical virology.

Radioimmunoassay for detecting hepatitis B core antigen in serum from patients with chronic hepatitis B infection.

V. Carreño, J. Quiroga, J. Porres, 1985, Clinical chemistry.

Quantitation of hepatitis C virus in liver and peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection

G. Colucci, V. Carreño, S. Navas, 1998, Journal of medical virology.

Detection of hepatitis C virus (HCV) core–specific antibody suggests occult HCV infection among blood donors

J. Bartolomé, V. Carreño, A. Avellón, 2016, Transfusion.

Does Occult Hepatitis C Virus Infection Exist?

J. Bartolomé, V. Carreño, I. Castillo, 2008, Journal of Clinical Microbiology.

Role of cytokines in the response to erythropoietin in hemodialysis patients.

V. Carreño, M. Goicoechea, C. Caramelo, 1998, Kidney international.

Genetic diversity and tissue compartmentalization of hepatitis C virus (HCV) genome in blood mononuclear cells, liver and serum from chronic hepatitis C patients

V. Carreño, S. Navas, I. Castillo, 1998 .

Ultracentrifugation of Serum Samples Allows Detection of Hepatitis C Virus RNA in Patients with Occult Hepatitis C

J. Bartolomé, V. Carreño, I. Castillo, 2007, Journal of Virology.

Retreatment of chronic hepatitis C virus infection

V. Carreño, E. Marriott, J. Quiroga, 1994, The Lancet.

Retreatment of chronic hepatitis C with interferon-alpha.

V. Carreño, E. Marriott, J. Quiroga, 1992, The Journal of infectious diseases.

Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels

R. Selgas, J. Bartolomé, V. Carreño, 2010, Journal of medical virology.

Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients.

L. Inglada, L. Sanchez-Sicilia, I. Castillo, 1990, Hepatology.

Occult Hepatitis C Virus Infection in Patients with Diabetic Nephropathy: Epidemiological and Clinical Implications

R. Selgas, J. Bartolomé, V. Carreño, 2016 .

Immunoglobulin M antibody to hepatitis C virus during interferon therapy for chronic hepatitis C.

V. Carreño, E. Marriott, I. Castillo, 1992, Gastroenterology.

Virus‐specific effector CD4+ T‐cell responses in hemodialysis patients with hepatitis C virus infection

R. Selgas, D. Subirá, S. Castañón, 2004, Journal of medical virology.

Viral RNA Amplification among at Risk HCV-seronegative Dialysis Patients.

J. Bartolomé, V. Carreño, M. Arenas, 2014 .

Diagnosis of occult hepatitis C without the need for a liver biopsy

J. Bartolomé, V. Carreño, G. Barril, 2010, Journal of medical virology.

Serum Immunoglobulin G Antibodies to the GOR Autoepitope Are Present in Patients with Occult Hepatitis C Virus (HCV) Infection despite Lack of HCV-Specific Antibodies

J. Bartolomé, V. Carreño, I. Castillo, 2007, Clinical and Vaccine Immunology.

Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha.

V. Carreño, J. Quiroga, M. Pardo, 1994, Digestive diseases and sciences.

Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells.

V. Carreño, S. Navas, J. Quiroga, 1999, Cytokine.

Long‐term virological follow up of patients with occult hepatitis C virus infection

J. Bartolomé, V. Carreño, G. Barril, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Combined Hepatitis C Virus (HCV) Antigen-Antibody Detection Assay Does Not Improve Diagnosis for Seronegative Individuals with Occult HCV Infection

V. Carreño, I. Castillo, J. Quiroga, 2006, Journal of Clinical Microbiology.

The role of genomic and antigenomic HCV‐RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy

V. Carreño, I. Castillo, J. Quiroga, 2007, Alimentary pharmacology & therapeutics.

Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: evaluation of the bleeding risk

V. Carreño, U. Hedner, J. Quiroga, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome

Changcai Wang, V. Carreño, J. van Binsbergen, 1995, Hepatology.

Long-term follow-up study of serum IgM antibody to hepatitis C virus (HCV), HCV replication, and liver disease outcome in chronic hepatitis C.

V. Carreño, S. Navas, I. Castillo, 1994, The Journal of infectious diseases.

Hepatitis E virus seroprevalence in acute viral hepatitis in a developed country confirmed by a supplemental assay

V. Carreño, I. Castillo, J. Quiroga, 1996, Journal of medical virology.

Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage.

J A Quiroga, V. Carreño, J Martín, 1998, The Journal of infectious diseases.

HCV-indeterminate blood donors or occult HCV infection?

V. Carreño, J. Quiroga, 2005, The Lancet.

Occult hepatitis B virus and hepatitis C virus infections

J. Bartolomé, V. Carreño, I. Castillo, 2008, Reviews in medical virology.

Inhibition of albumin binding to hepatitis B virions by monoclonal antibody to the preS2 domain of the viral envelope.

W. Gerlich, V. Carreño, J. Quiroga, 1987, Digestion.

and Exist ? Does Occult Hepatitis C Virus Infection

J. Bartolomé, V. Carreño, I. Castillo, 2008 .

Positive Elisa 2 is pathologically relevant in Elisa-1-negative patients on hemodialysis.

V. Carreño, C. Caramelo, E. Marriott, 1992, Nephron.